iBio (NYSE:IBIO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of iBio (NYSE:IBIO) in a research note published on Wednesday. The firm issued a sell rating on the stock.

iBio Stock Performance

Shares of iBio stock opened at $3.41 on Wednesday. iBio has a fifty-two week low of $1.02 and a fifty-two week high of $49.80.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.